secwatch.observer — SEC 8-K summary
======================================

Issuer:     GERON CORP (GERN)
CIK:        0000886744
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0000950170-23-057772
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Geron reports Q3 2023 cash $381.9M, imetelstat FDA PDUFA June 16, 2024; new $100M ATM facility
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $381.9M as of Sep 30, 2023; $28.3M from warrant exercises in Q3.
- FDA PDUFA action date June 16, 2024 for imetelstat NDA in lower-risk MDS; EMA review expected by end 2024.
- Entered into $100M at-market issuance sales agreement with B. Riley; replaces prior expiring facility; 3% commission.
- Michelle Robertson appointed EVP, CFO; total operating expenses in Q3 $47.8M vs $40.2M YoY; FY2023 expense guidance $200-210M.
- Company expects to fund operations through Q3 2025 with existing cash, projected imetelstat revenues and loan facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886744/000095017023057772/0000950170-23-057772-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886744/000095017023057772/gern-20231101.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-057772

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer